How to Help Your Patients Save Money on Ambrisentan (Letairis): A Provider's Guide to Savings Programs

Cost is one of the most significant barriers to ambrisentan (Letairis) adherence. Brand Letairis has a retail cash price of approximately $13,000 to $14,200 per month. Generic ambrisentan, while dramatically less expensive, still costs around $2,000 to $2,100 per month without assistance. For PAH patients — many of whom are managing a serious chronic illness, reduced work capacity, and multiple medications — this cost burden is substantial. This guide equips your practice to proactively address affordability, reduce abandonment rates, and keep your patients on therapy.

Understanding the Ambrisentan Cost Landscape

Before recommending savings options, understand the cost structure:

Brand Letairis (Gilead Sciences): ~$13,000–$14,200/month at retail. Available through certified specialty pharmacies only. Savings programs (LEAP) available for commercially insured patients.

Generic ambrisentan: ~$2,000–$2,100/month at retail. Available at retail pharmacies and specialty pharmacies. Manufacturer savings programs (Zydus) and discount platforms available.

For most commercially insured patients on the brand, the LEAP copay program brings the cost to as little as $5 per month. For patients on generic ambrisentan, the Zydus copay program can reduce it to as little as $0. However, accessing these savings requires enrollment and proactive management by your practice team.

Program 1: LEAP — Letairis Education and Access Program

LEAP is Gilead's comprehensive support program for brand Letairis patients. It offers three tiers of financial support:

Letairis Co-Pay Coupon Program: For commercially insured patients, eligible patients pay as little as $5 per month. This program automatically enrolls eligible patients when prescribed brand Letairis through a certified specialty pharmacy.

LEAP Patient Assistance Program: For qualifying uninsured or underinsured patients, LEAP may provide brand Letairis at no cost through the Patient Assistance Program. Financial and insurance eligibility criteria apply.

LEAP Medicare Support: LEAP helps Medicare patients understand their benefits and identifies third-party financial assistance resources — separate from manufacturer copay programs, which cannot be used with Medicare.

Contact: 1-866-664-5327 | letairis.com/patients/financial-resources

Important note for providers: The Letairis Co-Pay Coupon Program is NOT valid for patients with Medicare, Medicaid, TRICARE, VA, or any state/federal healthcare program. Prescribing for a patient who switches to government insurance without updating their savings program enrollment can result in billing issues.

Program 2: Zydus Copay Savings Program (Generic Ambrisentan)

Zydus Pharmaceuticals offers a copay savings program specifically for commercially insured patients taking generic ambrisentan (and bosentan). Eligible patients may pay as little as $0 per prescription, for up to 13 fills per year.

This program is particularly useful for patients whose insurance has switched them to generic ambrisentan (as many plans will prefer generics). As with all manufacturer savings programs, it does not apply to government insurance.

Strategies for Medicare Patients

Medicare patients face a different challenge — manufacturer copay programs are prohibited. Here are the most impactful strategies for this population:

Medicare Extra Help / Low Income Subsidy (LIS): Significantly reduces specialty drug cost-sharing for eligible patients. Refer patients who qualify to their local SHIP (State Health Insurance Assistance Program) counselor or the SSA office to apply.

PAH disease-specific foundations: HealthWell Foundation (healthwellfoundation.org) and the Patient Advocate Foundation (patientadvocate.org) offer disease funds that may cover copay or coinsurance for Medicare patients. Fund availability changes — check current status before referring.

Part D plan optimization: At open enrollment, help patients identify Part D plans with the best ambrisentan formulary tier and lowest specialty cost-sharing. A Medicare specialist or benefits counselor can assist with plan comparison.

LEAP Medicare support: Contact LEAP (1-866-664-5327) on behalf of Medicare patients — LEAP has resources for identifying available third-party assistance even though their co-pay coupon does not apply.

Formulary and Insurance Optimization Strategies

Your prescribing and documentation choices directly affect how quickly patients access ambrisentan and what they pay:

Prescribe generic ambrisentan by default. Most insurance plans prefer generics and will have lower specialty tier cost-sharing for generic ambrisentan compared to brand Letairis.

Submit thorough prior authorization documentation upfront. Include right heart catheterization data, WHO functional class, 6-minute walk distance, and current treatment. Complete documentation on first submission reduces delays and appeals.

Track PA renewals proactively. Specialty drug PAs typically require annual renewal. A lapsed PA creates a coverage gap that forces patients to pay out of pocket. Set calendar alerts at 30 and 60 days before expiration.

Use your specialty pharmacy's PA support services. Most specialty pharmacies have dedicated teams to manage prior authorization for PAH medications. Partner with one that has experienced authorization staff.

Practice Workflow: A Savings Checklist for New Ambrisentan Patients

When starting a patient on ambrisentan, run through this checklist:

Verify insurance type (commercial, Medicare, Medicaid, uninsured)

Prescribe generic ambrisentan unless brand is clinically justified

For commercial insurance: ensure LEAP or Zydus copay program enrollment is initiated

For Medicare: check Extra Help eligibility; contact LEAP for assistance resources

For uninsured: initiate LEAP Patient Assistance Program application

Submit prior authorization with complete documentation

Educate patient on refilling early (10 to 14 days before running out) and using medfinder if access issues arise

The Bottom Line

Ambrisentan affordability is manageable for most patients with the right combination of manufacturer programs, insurance optimization, and proactive PA management. Building these workflows into your practice infrastructure — rather than addressing them ad hoc — makes the biggest difference in patient adherence and outcomes. For help with access challenges beyond cost, see our guide on helping patients find ambrisentan in stock. Visit medfinder.com/providers to learn how medfinder supports PAH provider practices.